Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & Administrative
Others
Ratios

Alx Oncology Holdings (ALXO) Shares Outstanding (Weighted Average) (2019 - 2023)

Alx Oncology Holdings' Shares Outstanding (Weighted Average) history spans 5 years, with the latest figure at $41.1 million for Q3 2023.

  • For Q3 2023, Shares Outstanding (Weighted Average) rose 0.98% year-over-year to $41.1 million; the TTM value through Sep 2023 reached $41.1 million, up 0.98%, while the annual FY2022 figure was $40.7 million, 0.97% up from the prior year.
  • Shares Outstanding (Weighted Average) for Q3 2023 was $41.1 million at Alx Oncology Holdings, up from $40.9 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $41.1 million in Q3 2023 and bottomed at $3.1 million in Q4 2019.
  • The 5-year median for Shares Outstanding (Weighted Average) is $40.2 million (2021), against an average of $28.3 million.
  • The largest annual shift saw Shares Outstanding (Weighted Average) surged 1174.37% in 2021 before it rose 0.45% in 2023.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $3.1 million in 2019, then skyrocketed by 500.86% to $18.5 million in 2020, then soared by 118.05% to $40.3 million in 2021, then grew by 0.97% to $40.7 million in 2022, then increased by 1.1% to $41.1 million in 2023.
  • Per Business Quant, the three most recent readings for ALXO's Shares Outstanding (Weighted Average) are $41.1 million (Q3 2023), $40.9 million (Q2 2023), and $40.9 million (Q1 2023).